J Korean Med Assoc.  2004 Jul;47(7):631-635. 10.5124/jkma.2004.47.7.631.

Medical Treatment of Ischemic Stroke

• Yoon BW

• KMID: 2183481
• DOI: http://doi.org/10.5124/jkma.2004.47.7.631

Abstract

Stroke ranks as one of the leading causes of death and the most common cause of permanent disability in adults in Korea. Timely recognition and treatment is imperative to reduce stroke-related morbidity and mortality. Patients with acute ischemic stroke should be evaluated for intravenous thrombolysis with recombinant tissue-plasminogen activator (rt-PA); antiplatelet drugs can be administered to those who do not qualify for rt-PA therapy. Adequate hydration and correction of possible hypoxia are necessary, and hyperglycemia and fever should be treated aggressively. Blood pressure management should be individualized on the basis of stroke pathophysiology. It is important to prevent and manage complications of acute stroke, such as pneumonia, urinary tract infection, bed sore, deep vein thrombosis, and joint contracture. Meticulous evaluation of etiology of ischemic stroke can determine the most appropriate acute management and would guide the secondary prevention of stroke.

Keyword

Ischemic stroke; Thrombolysis; Keywords; Antiplatelet; Anticoagulation; Secondary prevention

MeSH Terms

Adult
Anoxia
Blood Pressure
Cause of Death
Contracture
Fever
Humans
Hyperglycemia
Joints
Korea
Mortality
Platelet Aggregation Inhibitors
Pneumonia
Pressure Ulcer
Secondary Prevention
Stroke*
Urinary Tract Infections
Venous Thrombosis
Platelet Aggregation Inhibitors

Reference

1. Alberts MJ, Bertels CD, Dawson DV. An analysis of the time of presentation after stroke. JAMA. 1990. 263:65–68.

2. Langhorne P, Williams BO, Gilchrist W, Howle K. Do stroke units save lives? Lancet. 1993. 342:395–398.

3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995. 333:1581–1587.

4. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study(ECASS). JAMA. 1995. 274:1017–1025.

5. Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Thies W, et al. Guidelines for thrombolytic therapy for acute stroke : a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation. 1996. 94:1167–1174.

6. International Stroke Trial Collaborative Group. The International Stroke Trial (IST) : a randomized trial of aspirine, subcutaneous heparin, both, or neither among 10,435 patients with acute ischemic stroke. Lancet. 1997. 349:1569–1581.

7. CAST : randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997. 349:1641–1649.

8. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996. 143:1–13.

9. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk for ischemic events (CAPRIE). Lancet. 1996. 348:1329–1339.

10. McCarthy ST, Turner JJ, Robertson D, Hawkey CJ. Low dose heparin as a prophylaxis against deep vein thrombosis after acute stroke. Lancet. 1977. 2:800–801.

11. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Gent M, et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet. 1987. 1:523–526.

12. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Wong A, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995. 333:1588–1593.

13. The Publication Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke : a randomized controlled trial. JAMA. 1998. 279:1265–1267.

14. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischemc stroke and atrial fibrillation : a double blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000. 355:1205–1210.

15. The European Ad Hoc Consensus Group. Optimizing intensive care in stroke : a European perspective. Cerebrovasc Dis. 1997. 7:113–128.

16. Reith J, Jorgensen HS, Pedersen PM, Nakayama H, Raaschou HO, Olsen TS, et al. Body temperature in acute stroke : relation to stroke severity, infarct size, mortality, and outcome. Lancet. 1996. 347:422–425.